HRP20202051T1 - Aril supstituirani pirimidini za uporabu kod infekcije virusom influence - Google Patents
Aril supstituirani pirimidini za uporabu kod infekcije virusom influence Download PDFInfo
- Publication number
- HRP20202051T1 HRP20202051T1 HRP20202051TT HRP20202051T HRP20202051T1 HR P20202051 T1 HRP20202051 T1 HR P20202051T1 HR P20202051T T HRP20202051T T HR P20202051TT HR P20202051 T HRP20202051 T HR P20202051T HR P20202051 T1 HRP20202051 T1 HR P20202051T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- compound
- polymorph
- solvate
- influenza virus
- Prior art date
Links
- 241000712461 unidentified influenza virus Species 0.000 title claims 2
- 125000003118 aryl group Chemical group 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 230000009385 viral infection Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 229960003971 influenza vaccine Drugs 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Claims (7)
1. Spoj odabran od
[image]
[image]
njegov stereoizomerni oblik, farmaceutski prihvatljiva sol, solvat ili polimorf.
2. Farmaceutski pripravak naznačen time što sadrži spoj prema zahtjevu 1 ili njegov stereoizomerni oblik, farmaceutski prihvatljivu sol, solvat ili polimorf, zajedno s jednim ili više farmaceutski prihvatljivih pomoćnih sredstava, razrjeđivača ili nosača.
3. Spoj prema patentnom zahtjevu 1 ili njegov stereoizomerni oblik, njegova farmaceutski prihvatljiva sol, solvat ili polimorf ili farmaceutski pripravak prema zahtjevu 2 naznačen time što se koristi kao lijek.
4. Spoj prema patentnom zahtjevu 1 ili njegov stereoizomerni oblik, njegova farmaceutski prihvatljiva sol, solvat ili polimorf ili farmaceutski pripravak prema zahtjevu 2 naznačen time što se koristi u liječenju influence.
5. Spoj prema patentnom zahtjevu 1 naznačen time što se koristi za inhibiranje replikacije virusa influence u biološkom uzorku ili pacijentu.
6. Spoj za uporabu prema patentnom zahtjevu 5 naznačen time što nadalje obuhvaća istodobnu primjenu dodatnog terapijskog sredstva.
7. Spoj za uporabu prema patentnom zahtjevu 6 naznačen time što se dodatno terapijsko sredstvo bira između antivirusnog sredstva ili cjepiva protiv influence, ili oboje.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16152095 | 2016-01-20 | ||
| PCT/EP2017/051105 WO2017125506A1 (en) | 2016-01-20 | 2017-01-19 | Aryl substituted pyrimidines for use in influenza virus infection |
| EP17700580.8A EP3405466B1 (en) | 2016-01-20 | 2017-01-19 | Aryl substituted pyrimidines for use in influenza virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20202051T1 true HRP20202051T1 (hr) | 2021-02-19 |
Family
ID=55345663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20202051TT HRP20202051T1 (hr) | 2016-01-20 | 2020-12-22 | Aril supstituirani pirimidini za uporabu kod infekcije virusom influence |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10611755B2 (hr) |
| EP (1) | EP3405466B1 (hr) |
| JP (1) | JP6989509B2 (hr) |
| KR (1) | KR20180100375A (hr) |
| CN (1) | CN108473477B (hr) |
| AU (1) | AU2017209925B2 (hr) |
| BR (1) | BR112018014794A2 (hr) |
| CA (1) | CA3010327A1 (hr) |
| CL (1) | CL2018001960A1 (hr) |
| CO (1) | CO2018007669A2 (hr) |
| DK (1) | DK3405466T3 (hr) |
| EA (1) | EA201891666A1 (hr) |
| EC (1) | ECSP18061667A (hr) |
| ES (1) | ES2850575T3 (hr) |
| HR (1) | HRP20202051T1 (hr) |
| HU (1) | HUE053078T2 (hr) |
| LT (1) | LT3405466T (hr) |
| MX (1) | MX2018008803A (hr) |
| SI (1) | SI3405466T1 (hr) |
| WO (1) | WO2017125506A1 (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS55341B1 (sr) | 2009-06-17 | 2017-03-31 | Vertex Pharma | Inhibitori replikacije virusa gripa |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| EP3294735B8 (en) | 2015-05-13 | 2022-01-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| SI3380467T1 (sl) | 2015-11-27 | 2021-08-31 | Janssen Sciences Ireland Unlimited Company | Heterociklični indoli za uporabo v okužbi z virusom gripe |
| LT3405466T (lt) * | 2016-01-20 | 2021-01-25 | Janssen Sciences Ireland Unlimited Company | Arilu pakeistieji pirimidinai, skirti naudoti gripo viruso infekcijos atveju |
| CN107759571B (zh) * | 2016-08-16 | 2021-03-02 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其使用方法和用途 |
| WO2018041091A1 (en) | 2016-08-30 | 2018-03-08 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| CN108218873B (zh) | 2016-12-15 | 2020-07-07 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其用途 |
| US11098042B2 (en) | 2017-01-05 | 2021-08-24 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
| WO2018157830A1 (en) | 2017-03-02 | 2018-09-07 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
| EA202191890A1 (ru) | 2019-01-18 | 2022-02-03 | Астразенека Аб | Ингибиторы pcsk9 и способы их применения |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG151327A1 (en) | 2005-09-30 | 2009-04-30 | Vertex Pharmaceuticals Incopor | Deazapurines useful as inhibitors of janus kinases |
| WO2008095999A1 (en) * | 2007-02-08 | 2008-08-14 | Tibotec Pharmaceuticals Ltd. | Pyrimidine substituted macrocyclic hcv inhibitors |
| RS55341B1 (sr) | 2009-06-17 | 2017-03-31 | Vertex Pharma | Inhibitori replikacije virusa gripa |
| ES2602972T3 (es) | 2010-09-08 | 2017-02-23 | Glaxosmithkline Intellectual Property Development Limited | Derivados de indazol para su uso en el tratamiento de infección por virus de la gripe |
| CN103492381A (zh) | 2010-12-16 | 2014-01-01 | 沃泰克斯药物股份有限公司 | 流感病毒复制的抑制剂 |
| CN103562205A (zh) | 2010-12-16 | 2014-02-05 | 沃泰克斯药物股份有限公司 | 流感病毒复制的抑制剂 |
| ES2887303T3 (es) * | 2011-04-08 | 2021-12-22 | Janssen Sciences Ireland Unlimited Co | Derivados de pirimidina para el tratamiento de infecciones víricas |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| WO2013184985A1 (en) * | 2012-06-08 | 2013-12-12 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| AR093020A1 (es) * | 2012-10-16 | 2015-05-13 | Janssen R&D Ireland | Compuestos antiviricos para el vsr |
| CN105189468B (zh) * | 2013-02-21 | 2018-10-30 | 爱尔兰詹森科学公司 | 用于治疗病毒性感染的2-氨基嘧啶衍生物 |
| SI3380467T1 (sl) | 2015-11-27 | 2021-08-31 | Janssen Sciences Ireland Unlimited Company | Heterociklični indoli za uporabo v okužbi z virusom gripe |
| LT3405466T (lt) * | 2016-01-20 | 2021-01-25 | Janssen Sciences Ireland Unlimited Company | Arilu pakeistieji pirimidinai, skirti naudoti gripo viruso infekcijos atveju |
-
2017
- 2017-01-19 LT LTEP17700580.8T patent/LT3405466T/lt unknown
- 2017-01-19 MX MX2018008803A patent/MX2018008803A/es unknown
- 2017-01-19 EP EP17700580.8A patent/EP3405466B1/en active Active
- 2017-01-19 DK DK17700580.8T patent/DK3405466T3/da active
- 2017-01-19 SI SI201730580T patent/SI3405466T1/sl unknown
- 2017-01-19 CN CN201780007200.1A patent/CN108473477B/zh not_active Expired - Fee Related
- 2017-01-19 US US16/071,649 patent/US10611755B2/en not_active Expired - Fee Related
- 2017-01-19 BR BR112018014794A patent/BR112018014794A2/pt not_active IP Right Cessation
- 2017-01-19 CA CA3010327A patent/CA3010327A1/en active Pending
- 2017-01-19 KR KR1020187022179A patent/KR20180100375A/ko not_active Application Discontinuation
- 2017-01-19 WO PCT/EP2017/051105 patent/WO2017125506A1/en active Application Filing
- 2017-01-19 AU AU2017209925A patent/AU2017209925B2/en not_active Ceased
- 2017-01-19 ES ES17700580T patent/ES2850575T3/es active Active
- 2017-01-19 JP JP2018537626A patent/JP6989509B2/ja active Active
- 2017-01-19 HU HUE17700580A patent/HUE053078T2/hu unknown
- 2017-01-19 EA EA201891666A patent/EA201891666A1/ru unknown
-
2018
- 2018-07-19 CL CL2018001960A patent/CL2018001960A1/es unknown
- 2018-07-24 CO CONC2018/0007669A patent/CO2018007669A2/es unknown
- 2018-08-15 EC ECSENADI201861667A patent/ECSP18061667A/es unknown
-
2020
- 2020-04-03 US US16/840,279 patent/US11117887B2/en active Active
- 2020-12-22 HR HRP20202051TT patent/HRP20202051T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019507119A (ja) | 2019-03-14 |
| JP6989509B2 (ja) | 2022-01-05 |
| US10611755B2 (en) | 2020-04-07 |
| DK3405466T3 (da) | 2021-02-01 |
| ECSP18061667A (es) | 2018-10-31 |
| US20190047989A1 (en) | 2019-02-14 |
| MX2018008803A (es) | 2018-11-09 |
| CN108473477B (zh) | 2021-10-22 |
| WO2017125506A1 (en) | 2017-07-27 |
| EA201891666A1 (ru) | 2019-01-31 |
| BR112018014794A2 (pt) | 2018-12-11 |
| AU2017209925B2 (en) | 2021-04-08 |
| SI3405466T1 (sl) | 2021-02-26 |
| LT3405466T (lt) | 2021-01-25 |
| CO2018007669A2 (es) | 2018-08-10 |
| EP3405466A1 (en) | 2018-11-28 |
| ES2850575T3 (es) | 2021-08-30 |
| EP3405466B1 (en) | 2020-11-18 |
| HUE053078T2 (hu) | 2021-06-28 |
| CA3010327A1 (en) | 2017-07-27 |
| CL2018001960A1 (es) | 2018-08-31 |
| CN108473477A (zh) | 2018-08-31 |
| US11117887B2 (en) | 2021-09-14 |
| US20200231577A1 (en) | 2020-07-23 |
| AU2017209925A1 (en) | 2018-07-12 |
| KR20180100375A (ko) | 2018-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20202051T1 (hr) | Aril supstituirani pirimidini za uporabu kod infekcije virusom influence | |
| HRP20210038T1 (hr) | Pirolopirimidini za uporabu u infekciji virusom gripe | |
| HRP20211278T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| HRP20211223T1 (hr) | Heterociklički indoli za upotrebu kod infekcije virusom influence | |
| CY1121698T1 (el) | Υγρο σκευασμα για εισπνοη που περιεχει rpl554 | |
| HRP20211749T1 (hr) | Pentanske kiseline supstituirane pirolo-[2-3,b]pirimidin-piridinima za liječenje virusnih infekcija influencom | |
| HRP20230274T1 (hr) | Kemijski spojevi | |
| HRP20200408T1 (hr) | Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| HRP20171512T1 (hr) | Derivati betulina | |
| EA201791019A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
| CL2017002022A1 (es) | Composiciones farmaceuticas que contienen n-(3,5-dimetilfosfeno) - n'-(1-metiletil) - n - [3-(1-metil-1h-pirazol-4-yl) quinoxalina - 6 - yl] etano -1,2 - diamina | |
| JP2019510027A5 (hr) | ||
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| MX2017012393A (es) | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. | |
| JP2016508134A5 (hr) | ||
| CU20170109A7 (es) | Derivado de quinoleina para tratar y prevenir infecciones virales | |
| TR201908994T4 (tr) | Farmasötik bileşimler. | |
| HRP20201645T1 (hr) | Triterpenoidi s aktivnošću inhibiranja zrenja hiv, supstituirani na položaju 3 nearomatskim prstenom koji nosi halogenalkilni supstituent | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| HRP20201187T1 (hr) | Derivat triazolopirazinona koristan kao inhibitor ljudskog pde1 | |
| BR112019018028A2 (pt) | Composto, combinação, e. uso de um composto ou um sal farmaceuticamente aceitável do mesmo | |
| EP4292658A3 (en) | Alkynyl nucleoside analogs as inhibitors of human rhinovirus | |
| RU2015131803A (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения |